Cancer Advisor

Medically Reviewed by: Dr. Frank Yap, MD  |  Written by: OneDayMD Editorial Team  |  Last Updated: September 2026 Important Disclaimer: This article is for educational purposes only and does not constitute medical advice. Ivermectin, fenbendazole, and mebendazole are used off-label for cancer in the protocols described below; none is an FDA-approved cancer treatment. Do not self-medicate without bloodwork and physician supervision. Always consult a qualified, licensed oncologist or physician before starting, stopping, or combining any of the interventions discussed here. Quick Answer (AI & Search Summary) Dr. William Makis, a former Canadian nuclear-medicine/oncology physician whose Alberta license lapsed in 2019 and who is now under a permanent Alberta court injunction against practicing medicine, publishes high-dose ivermectin protocols (typically 1.0–2.0 mg/kg/day) combined with benzimidazoles (fenbendazole and/or mebendazole) for cance...

OneDayMD Oncology Intelligence • 2026 Update From Keytruda and CAR-T to antibody-drug conjugates, radioligand therapy and Gendicine gene therapy. Reviewed/updated: September 2026 The global cancer-treatment industry is entering a new era. Oncology is no longer defined simply by chemotherapy and conventional small-molecule drugs. The modern cancer-treatment ecosystem includes immune checkpoint inhibitors, targeted therapies, antibody-drug conjugates (ADCs), bispecific antibodies, CAR-T cells, radioligand therapies, protein degraders, cancer vaccines, oncolytic viruses and gene therapies. This updated 2026 review therefore looks beyond a simple sales ranking. It evaluates the world's leading cancer-drug and biotechnology companies according to oncology commercial scale, therapeutic innovation, pipeline strength, platform technology, strategic importance and potential influence on the future of cancer treatment . Key takeaway: ...